Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (811)	4/1/1998 4:21:00 PM
From: john w. toigo	Respond to of 1432

Baxter trial news concern: While the Baxter and Biotime products differ in their origin and in their indications regarding O2 carrying capacity, I'm concerned that the extensive trials required for the Baxter product could nevertheless suggest some of the regulatory hurdles still facing BTIM's Hextend. I'm long BTIM, and hopeful, but it's risky to be too optimistic at this very early stage in the submission. As a regulatory affairs professional, I'm not at all sure that they'll be able to sustain the expedited review petition since there are other products already out there with the same/similar indications. Does anyone have info and the Medicare/Medicaid reimbursement schedule for Hextend? Any constructive comments appreciated. Thanks/JWT